Enhanced Oral Bioavailability of Doxorubicin in a Dendrimer Drug Delivery System

Ke, Weilun; Zhao, Yuwu; Huang, Rongqin; Jiang, Chen; Pei, Yuanying

doi:10.1002/jps.21155

Cited by 146 publications

(88 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Also, there are preclinical promising in vitro and in vivo results with active targeting dendrimers [73,365], for example antibody-dendrimer conjugates showed better efficacy than free antibodies [380][381][382][383], peptide (RGD) dendrimer conjugates showed enhanced tumor targeting [384][385][386], and folic acid functionalized dendrimers generated better tumor accumulations than untargeted controls or free drug, producing a stronger reduction of the tumor size [73,[387][388][389][390]. The slow translation of these preclinical studies to clinical trials may be due to the current toxicity of dendrimers [391,392], with the aim of the current research in the development of new biocompatible and less toxic alternatives [367,[393][394][395][396][397][398][399].…”

Section: Polymeric Nanocarriersmentioning

confidence: 99%

Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy

Pérez-Herrero

Fernández‐Medarde

2015

European Journal of Pharmaceutics and Biopharmaceutics

1,396

754

View full text Add to dashboard Cite

Cancer is the second worldwide cause of death, exceeded only by cardiovascular diseases. It is characterized by uncontrolled cell proliferation and an absence of cell death that, except for hematological cancers, generates an abnormal cell mass or tumor. This primary tumor grows thanks to new vasculatization and, in time, adquires metastatic potential and spreads to other body sites, which causes metastasis and finally death. Cancer is caused by damage or mutations in the genetic material of the cells due to environmental or inherited factors. While surgery and radiotherapy are the primary treatment used for local and non-metastatic cancers, anti-cancer drugs (chemotherapy, hormone and biological therapies) are the choice currently used in metastasic cancers. Chemotherapy is based on the inhibition of the division of rapidly growing cells, which is a characteristic of the cancerous cells, but unfortunately, it also affects normal cells with fast proliferation rates, like the hair follicles, bone marrow and gastrointestinal tract cells, generating the characteristic side effects of chemotherapy. The indiscriminate destruction of normal cells, the toxicity of conventional chemotherapeutic Código de campo cambiado

show abstract

Section: Polymeric Nanocarriersmentioning

confidence: 99%

Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy

Pérez-Herrero

Fernández‐Medarde

2015

European Journal of Pharmaceutics and Biopharmaceutics

1,396

754

View full text Add to dashboard Cite

show abstract

“…The results reported a 300 fold increase in bioavailability of the doxorubicin when delivered as PAMAM-doxorubicin conjugate as compared to the free drug following a single oral dose in rats. 58 Studies in our lab involved covalent conjugation as well as complexation of 7-ethyl-10-hydroxy-camptothecin (SN-38), a potent topoisomerase inhibitor and a biologically active metabolite of irinotecan hydrochloride, with PAMAM dendrimers. Initially, SN-38 was complexed to PAMAM G4.0-NH 2 , and its permeability was assessed across Caco-2 monolayers.…”

Section: Pamam-dendrimer-drug Conjugates and Complexes For Oral Deliverymentioning

confidence: 99%

Poly(amido amine) dendrimers in oral delivery

Yellepeddi

Ghandehari

2016

Tissue Barriers

View full text Add to dashboard Cite

Poly(amidoamine) (PAMAM) dendrimers have been extensively investigated for oral delivery applications due to their ability to translocate across the gastrointestinal epithelium. In this Review, we highlight recent advances in the evaluation of PAMAM dendrimers as oral drug delivery carriers. Specifically, toxicity, mechanisms of transepithelial transport, models of the intestinal epithelial barrier including isolated human intestinal tissue model, detection of dendrimers, and surface modification are discussed. We also highlight evaluation of various PAMAM dendrimer-drug conjugates for their ability to transport across gastrointestinal epithelium for improved oral bioavailability. In addition, current challenges and future trends for clinical translation of PAMAM dendrimers as carriers for oral delivery are discussed.

show abstract

“…Often drugs are not compatible with use of the protein transporter system that is designed to pass nutrients. The oral route using dendrimers looks very promising especially with anticancer and antihypertensive drugs [23,[71][72][73][74][75].…”

Section: Oral Drug Deliverymentioning

confidence: 99%

Polyester Dendrimers: Smart Carriers for Drug Delivery

Twibanire

Grindley

2014

Polymers

View full text Add to dashboard Cite

Polyester dendrimers have been shown to be outstanding candidates for biomedical applications. Compared to traditional polymeric drug vehicles, these biodegradable dendrimers show excellent advantages especially as drug delivery systems because they are non-toxic. Here, advances on polyester dendrimers as smart carriers for drug delivery applications have been surveyed. Both covalent and non-covalent incorporation of drugs are discussed.

show abstract

Enhanced Oral Bioavailability of Doxorubicin in a Dendrimer Drug Delivery System

Cited by 146 publications

References 25 publications

Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy

Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy

Poly(amido amine) dendrimers in oral delivery

Polyester Dendrimers: Smart Carriers for Drug Delivery

Contact Info

Product

Resources

About